#United States #Phoenix #SkinCure Oncology #GentleCure #Image-Guided SRT

SkinCure Oncology Celebrates Major Treatment Milestone

In an impressive milestone for skin cancer treatment, SkinCure Oncology announced that it has successfully treated its 100,000th patient using their innovative GentleCure method, a non-invasive approach developed for patients with nonmelanoma skin cancer (NMSC). This milestone was reached with the treatment of Patty Focken, a resident of Phoenix, Arizona, who has a history of enjoying outdoor activities, highlighting the need for effective skin cancer solutions as rates of the disease continue to increase.

Leading the Way in Non-Surgical Treatments

SkinCure Oncology has established itself as a pioneer in the field of dermatology by focusing on Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), a safer, non-surgical treatment alternative for NMSC. This industry-leading model combines low-dose X-rays with high-definition imaging to precisely target cancerous cells while ensuring minimal damage to surrounding healthy tissue. With a reported cure rate exceeding 99%, patients like Focken have benefitted greatly from this revolutionary treatment option that also minimizes recovery time and scarring compared to traditional surgical methods such as Mohs surgery.

The GentleCure Experience

When discussing her journey, Patty Focken shared the concerns she faced during her initial diagnosis with NMSC in 2021. Upon being advised to undergo surgery by her first two dermatologists, Focken discovered the Gentleman noninvasive treatment option through her research. The appeal of avoiding post-surgical scarring was a decisive factor in her quest for alternative therapies. Once she found a provider in Phoenix, she opted for GentleCure treatments, ultimately leading to the successful resolution of her skin cancer in a series of brief sessions that required only minutes of her time.

Focken's case exemplifies the typically quick and painless nature of the GentleCure process, which has garnered patient satisfaction rates exceeding 99%. The method's efficiency and effectiveness remain paramount as more dermatologists increasingly recognize it as a viable treatment choice.

Dermatological Community Response

Dr. Genevieve Egnatios, Focken’s dermatologist, emphasized the crucial nature of skin cancer prevention and early detection during a recent interview. NMSC is categorized as the most prevalent type of cancer in the United States, impacting over 3.3 million individuals annually. With its effectively treatable nature, many healthcare providers are eager to involve patients in discussions about all available treatment options.

He noted that patient involvement is key, allowing them to weigh the benefits of advanced technological solutions like GentleCure against other methods. In the evolving landscape of healthcare, accepting groundbreaking therapy like Image-Guided SRT is vital to ensuring patients receive the best care tailored to their individual needs.

The Future of Skin Cancer Treatment

As SkinCure’s Chief Executive Officer Kerwin Brandt pointed out, the increasing adoption of GentleCure therapy underscores the demand for innovative treatment methods that prioritize patient comfort and recovery. With more than 500 physicians now providing GentleCure across the nation, SkinCure Oncology is committed to extending access to this advanced therapy nationwide.

Focken looks forward to a future where she can continue enjoying outdoor activities with her grandchildren, now with an emphasis on proactive measures for skin protection like high-SPF sunscreen and protective clothing. She is determined to share her experience with friends and family, encouraging them to explore the GentleCure option should the need arise.

For more information about SkinCure Oncology and the GentleCure treatment, interested individuals can visit SkinCureOncology.com and GentleCure.com for further insights and patient support resources.